LabPLUS now accredited to perform Minimal Residual Disease (MRD) studies
Our flow cytometry laboratory is now accredited to perform Minimal Residual Disease (MRD) studies following the Children's Oncology Group protocols on paediatric patients with B Acute Lymphoblastic Leukaemia. MRD is highly prognostic in paediatric B-ALL and MRD testing is now standard of care.
Michelle Petrasich, Edward Theakston, George Chan and Anna Ruskova have worked very hard to achieve this accreditation, the first in New Zealand. Congratulations to them all.